The clinical performance is complex and often involves multi-systematic stress. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
Platforms can help align a team of authoritative experts at home and abroad to provide accurate diagnostics and treatment plans. Individualised development of treatment plans for treatment and management of pulmonary tumors typically includes drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to the changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of pulmonary tumors. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumors, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.